Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NervGen Pharma Corp. - Common stock (NQ:NGEN)

4.230 +0.050 (+1.20%)
Streaming Delayed Price Updated: 11:35 AM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 27,015
Open 4.170
Bid (Size) 4.160 (100)
Ask (Size) 4.240 (200)
Prev. Close 4.180
Today's Range 4.160 - 4.280
52wk Range 3.510 - 6.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
From NervGen Pharma Corp.
Via GlobeNewswire

Performance

YTD
-29.1%
-29.1%
1 Month
+1.9%
+1.9%
3 Month
-29.1%
-29.1%
6 Month
-29.1%
-29.1%
1 Year
-29.1%
-29.1%

More News

Read More
News headline image
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Participate at Upcoming Investor Conferences
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
From NervGen Pharma Corp.
Via GlobeNewswire

Frequently Asked Questions

Is NervGen Pharma Corp. - Common stock publicly traded?
Yes, NervGen Pharma Corp. - Common stock is publicly traded.
What exchange does NervGen Pharma Corp. - Common stock trade on?
NervGen Pharma Corp. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for NervGen Pharma Corp. - Common stock?
The ticker symbol for NervGen Pharma Corp. - Common stock is NGEN on the Nasdaq Stock Market
What is the current price of NervGen Pharma Corp. - Common stock?
The current price of NervGen Pharma Corp. - Common stock is 4.230
When was NervGen Pharma Corp. - Common stock last traded?
The last trade of NervGen Pharma Corp. - Common stock was at 04/09/26 11:35 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.